We are live on ! Find out more
NEOS

Neos Therapeutics, Inc
NEOS

Delisted

NEOS was delisted on the 19th of March, 2021.

63 hedge funds and large institutions have $121M invested in Neos Therapeutics, Inc in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 12 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 12

37% more capital invested

Capital invested by funds: $88.5M → $121M (+$33M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

6% less funds holding

Funds holding: 6763 (-4)

21% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 14

28% less call options, than puts

Call options by funds: $466K | Put options by funds: $647K

Holders
63
Holders Change
-4
Holders Change %
-5.97%
% of All Funds
1.57%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
11
Increased
30
Reduced
12
Closed
14
Calls
$466K
Puts
$647K
Net Calls
-$181K
Net Calls Change
-$249K
Name Holding Trade Value Shares
Change
Change in
Stake
Franklin Resources
1
Franklin Resources
California
$21.4M +$1.26M +165,300 +8%
DM
2
Deerfield Management
New York
$14.4M +$834K +109,726 +8%
BlackRock
3
BlackRock
New York
$13M +$3.41M +448,341 +46%
Millennium Management
4
Millennium Management
New York
$9.78M +$3.61M +475,447 +80%
DA
5
DSC Advisors
Illinois
$9.55M
Vanguard Group
6
Vanguard Group
Pennsylvania
$8.32M +$1.29M +169,173 +23%
JGC
7
J. Goldman & Co
New York
$5.82M -$1.59M -209,135 -25%
CAM
8
Cortina Asset Management
Wisconsin
$5.31M +$4.41M +580,503 New
GTC
9
Ghost Tree Capital
New York
$3.66M -$760K -100,000 -20%
State Street
10
State Street
Massachusetts
$3.25M +$290K +38,136 +12%
Russell Investments Group
11
Russell Investments Group
United Kingdom
$2.51M +$30.9K +4,067 +2%
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$2.33M +$1.49M +196,589 +337%
Northern Trust
13
Northern Trust
Illinois
$2.33M +$407K +53,616 +27%
EIM
14
Essex Investment Management
Massachusetts
$2.18M +$353K +46,423 +24%
LSC
15
Lyon Street Capital
California
$2.06M +$1.71M +225,466 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.61M +$369K +48,618 +38%
CCI
17
Columbus Circle Investors
$1.58M -$760K -100,057 -37%
FPC
18
Falcon Point Capital
California
$1.21M -$43.3K -5,694 -5%
Wells Fargo
19
Wells Fargo
California
$1.08M +$485K +63,832 +118%
SBIA
20
Sheaff Brock Investment Advisors
Indiana
$915K +$760K +100,000 New
PCM
21
Prelude Capital Management
New York
$847K +$216K +28,410 +44%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$747K +$170K +22,363 +38%
UBS Group
23
UBS Group
Switzerland
$645K -$1.33M -174,516 -71%
Citadel Advisors
24
Citadel Advisors
Florida
$617K +$513K +67,442 New
TCIM
25
TIAA CREF Investment Management
New York
$541K +$93.5K +12,303 +26%

NEOS Hedge Fund Activity: Q3 2017 in Review

63 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q3 2017, worth a combined $121M — up 37% from $88.5M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of NEOS and 11 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 30 added.

The largest buyer was Cortina Asset Management, opening a new position worth an estimated $4.41M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $4.13M sold.

  • 63 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q3 2017, down from 67 in Q2 2017.
  • Funds reported $121M of Neos Therapeutics, Inc stock for Q3 2017, up 37% quarter-over-quarter.
  • 11 funds opened new Neos Therapeutics, Inc positions in Q3 2017 and 14 closed out, a net change of -3 holders.
  • The largest Neos Therapeutics, Inc buyer in Q3 2017 was Cortina Asset Management, an estimated $4.41M added.
  • The largest Neos Therapeutics, Inc seller in Q3 2017 was Stonepine Capital Management, an estimated $4.13M sold.

Based on aggregated 13F filings for Q3 2017.